- Home
- EDSA vs CDT Comparison
EDSA vs CDT Comparison
Compare EDSA & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- CDT
- Stock Information
- Founded
- EDSA 2015
- CDT 2019
- Country
- EDSA Canada
- CDT United States
- Employees
- EDSA N/A
- CDT N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- CDT Health Care
- Exchange
- EDSA Nasdaq
- CDT Nasdaq
- Market Cap
- EDSA 11.0M
- CDT 10.9M
- IPO Year
- EDSA N/A
- CDT N/A
- Fundamental
- Price
- EDSA $2.09
- CDT $0.09
- Analyst Decision
- EDSA Strong Buy
- CDT
- Analyst Count
- EDSA 1
- CDT 0
- Target Price
- EDSA $21.00
- CDT N/A
- AVG Volume (30 Days)
- EDSA 50.3K
- CDT 12.0M
- Earning Date
- EDSA 12-13-2024
- CDT 11-26-2024
- Dividend Yield
- EDSA N/A
- CDT N/A
- EPS Growth
- EDSA N/A
- CDT N/A
- EPS
- EDSA N/A
- CDT N/A
- Revenue
- EDSA N/A
- CDT N/A
- Revenue This Year
- EDSA N/A
- CDT N/A
- Revenue Next Year
- EDSA N/A
- CDT N/A
- P/E Ratio
- EDSA N/A
- CDT N/A
- Revenue Growth
- EDSA N/A
- CDT N/A
- 52 Week Low
- EDSA $2.09
- CDT $0.08
- 52 Week High
- EDSA $6.46
- CDT $7.83
- Technical
- Relative Strength Index (RSI)
- EDSA 19.32
- CDT 38.86
- Support Level
- EDSA $2.26
- CDT $0.09
- Resistance Level
- EDSA $2.44
- CDT $0.11
- Average True Range (ATR)
- EDSA 0.26
- CDT 0.01
- MACD
- EDSA -0.06
- CDT -0.00
- Stochastic Oscillator
- EDSA 0.00
- CDT 16.41
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.